News

Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...
Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Novo Nordisk Gains as CFO Touts Wegovy’s Rebound Potential
Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...
How copycats of Wegovy, Zepbound created a billion-dollar market
Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...
BioSpace15h
Novo Vows Smoother Market Waters for Wegovy—But Analysts Are Skeptical
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
US judge sides with FDA's removal of Lilly's weight loss drug from shortage list
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...
Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?
Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge
Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...
pharmaphorum2d
Lilly hit as PBM drops Zepbound, but retains Wegovy
Shares in Eli Lilly have weakened after CVS Health ... is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price ...
Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share.
Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...